These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27134509)

  • 1. Letter to the Editor: Should We Really Take Anti-Viral Therapy into Account in Chronic Hepatitis B Patients with Normal Liver Function?
    Khosravi MH; Alavian SM
    J Korean Med Sci; 2016 May; 31(5):824. PubMed ID: 27134509
    [No Abstract]   [Full Text] [Related]  

  • 2. How to overcome antiviral-resistant hepatitis B virus?
    Song BC
    Intervirology; 2010; 53(1):29-38. PubMed ID: 20068338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Chen J; Tu T; Cohen C; Wang S; Hsu YC; Gish RG
    Hepatology; 2024 May; 79(5):E132-E133. PubMed ID: 38150019
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiviral therapy of chronic hepatitis B.
    Zoulim F
    Antiviral Res; 2006 Sep; 71(2-3):206-15. PubMed ID: 16716414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL.
    Dai CY; Chuang WL; Huang JF; Yu ML
    Hepatology; 2009 Feb; 49(2):704-5; author reply 705-6. PubMed ID: 19177587
    [No Abstract]   [Full Text] [Related]  

  • 6. [Focusing on the markers for monitoring and antiviral therapy in chronic hepatitis B virus infection].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):836-7. PubMed ID: 17125613
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial.
    Huang L; Li J; Yan J; Sun J; Zhang X; Wu M; Yan Y
    J Viral Hepat; 2013 May; 20(5):336-42. PubMed ID: 23565616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proposed, evidence-based approach to the treatment of chronic Hepatitis B.
    Han SH; Durazo FA; Saab S; Tong MJ
    J Clin Gastroenterol; 2011 Mar; 45(3):259-66. PubMed ID: 20856136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antiviral treatment response on liver histopathology in chronic hepatitis B infection patients.
    Karacaer Z; Diktaş H
    Turk J Gastroenterol; 2016 Jan; 27(1):83-4. PubMed ID: 26620962
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.
    Hwang JP; Suarez-Almazor ME; Cantor SB; Barbo A; Lin HY; Ahmed S; Chavez-MacGregor M; Donato-Santana C; Eng C; Ferrajoli A; Fisch MJ; McLaughlin P; Simon GR; Rondon G; Shpall EJ; Lok AS
    Cancer; 2017 Sep; 123(17):3367-3376. PubMed ID: 28518219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aspects for long-term anti-viral therapy in treatment of chronic hepatitis B].
    Wang H
    Zhonghua Nei Ke Za Zhi; 2003 Jun; 42(6):367-8. PubMed ID: 14509984
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HBV mutations during antiviral therapy in patients with chronic hepatitis B].
    Hwang SG
    Korean J Hepatol; 2005 Dec; 11(4):311-9. PubMed ID: 16380660
    [No Abstract]   [Full Text] [Related]  

  • 15. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation.
    Philips CA; Sarin SK
    World J Gastroenterol; 2014 Nov; 20(43):16037-52. PubMed ID: 25473156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
    Fournier C; Zoulim F
    Clin Liver Dis; 2007 Nov; 11(4):869-92, ix. PubMed ID: 17981233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase.
    Lo GH
    Gastroenterology; 2014 Sep; 147(3):718-9. PubMed ID: 25075941
    [No Abstract]   [Full Text] [Related]  

  • 19. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.
    Zoulim F
    J Hepatol; 2005 Mar; 42(3):302-8. PubMed ID: 15710212
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis B virus infection--natural history and clinical consequences.
    Ganem D; Prince AM
    N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.